These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 27960557)

  • 21. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
    Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L
    Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update on anti-TNF agents in ulcerative colitis.
    Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
    Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
    [No Abstract]   [Full Text] [Related]  

  • 25. Golimumab: clinical update on its use for ulcerative colitis.
    Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
    Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.
    Lawrance IC
    Expert Opin Investig Drugs; 2015 Jun; 24(6):761-8. PubMed ID: 25719407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.
    Scott FI; Shah Y; Lasch K; Luo M; Lewis JD
    Inflamm Bowel Dis; 2018 Jan; 24(2):286-295. PubMed ID: 29361100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.
    Verstockt B; Claeys C; De Hertogh G; Van Assche G; Wolthuis A; D'Hoore A; Vermeire S; Ferrante M
    United European Gastroenterol J; 2019 Nov; 7(9):1215-1225. PubMed ID: 31700634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis.
    Galván-Banqueri M; Vega-Coca MD; Castillo-Muñoz MA; Beltrán Calvo C; Molina López T
    Farm Hosp; 2015 Mar; 39(2):80-91. PubMed ID: 25817087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?
    Allocca M; Fiorino G; Gilardi D; Preatoni P; Papa A; Peyrin-Biroulet L; Danese S
    Curr Drug Targets; 2018; 19(7):748-756. PubMed ID: 27231106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety of vedolizumab for the treatment of ulcerative colitis.
    Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
    Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
    Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
    McConachie S; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
    Toor K; Druyts E; Jansen JP; Thorlund K
    J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
    Paschos P; Katsoula A; Salanti G; Giouleme O; Athanasiadou E; Tsapas A
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1174-1185. PubMed ID: 30378141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and emerging biologics for ulcerative colitis.
    Park SC; Jeen YT
    Gut Liver; 2015 Jan; 9(1):18-27. PubMed ID: 25547087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of biologics in the treatment of patients with inflammatory bowel disease.
    Selinger CP; Carbery I; Al-Asiry J
    Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab.
    Armuzzi A; Pugliese D; Nardone OM; Guidi L
    Drug Des Devel Ther; 2013; 7():289-96. PubMed ID: 23630414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab in ulcerative colitis: hypes and hopes.
    Fiorino G; Peyrin-Biroulet L; Repici A; Malesci A; Danese S
    Expert Opin Biol Ther; 2011 Jan; 11(1):109-16. PubMed ID: 21133817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.